Advances in the controversies of neoadjuvant chemotherapy for advanced gastric cancer

doi:10.3877/cma.j.issn.1674-0793.2021.05.017

Abstract

Abstract:

Neoadjuvant chemotherapy for advanced gastric cancer has been becoming the hot-spot issue in clinic. The focus of the research is mainly on the selection of schemes and predictive factors. Neoadjuvant chemotherapy may improve the prognosis of gastric cancer patients whose tumor can not be radically resected at the first stage. However, there are still controversies about which pathological type of gastric cancer is suitable for neoadjuvant chemotherapy and which scheme of neoadjuvant chemotherapy will bring greater help to the patients. The purpose of this article is to summarize the relevant literatures on advanced gastric cancer in recent years and make the conclusion about the indication, prediction and evaluation of the chemotherapy regimen and the impact of neoadjuvant chemotherapy on surgery, so as to provide help of neoadjuvant chemotherapy for patients with advanced gastric cancer.

Key words: Advanced gastric cancer, Neoadjuvant chemotherapy

Yuhao Zhai, Zhi Zheng, Wei Deng, Zhigang Bai, Jie Yin, Jun Zhang. Advances in the controversies of neoadjuvant chemotherapy for advanced gastric cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2021, 15(05): 386-390.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2021.05.017

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2021/V15/I05/386

References 38

[1]	李子禹, 季鑫, 季加孚. 新辅助化疗对胃癌手术并发症的影响[J]. 中国实用外科杂志, 2013, 33(4): 275-278.
[2]	Frei E 3rd. Clinical cancer research: An embattled species[J]. Cancer, 1982, 50(10): 1979-1992.
[3]	Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20.
[4]	中华人民共和国国家卫生健康委员会. 胃癌诊疗规范(2018) . 2018-12-21.
[5]	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology[M/OL]: Gastric Cancer. Ver 3. 2020.[2020-8-14] URL
[6]	Yoshida K, Kazuya Y, Naoki O, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification[J]. Gastric Cancer, 2016, 19(2): 329-338.
[7]	Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5): 439-449.
[8]	Iwasaki Y, Sasako M, Yamamoto S, et al. Phase Ⅱ study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210)[J]. J Surg Oncol, 2013, 107(7): 741-745.
[9]	Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase Ⅲ trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG 0501)[J]. Gastric Cancer, 2019, 22(5): 1044-1052.
[10]	Xiang X, Su Y, Li G, et al. Phase Ⅱ study of preoperative intra-arterial epirubicin, etoposide, and oxaliplatin combined with oral S-1 chemotherapy for the treatment of Borrmann type 4 gastric cancer[J]. J Gastric Cancer, 2020, 20(4): 395-407.
[11]	Ji J, Shen L, Li Z, et al. LBA42 Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: A randomized phase Ⅲ trial (RESOLVE trial)[J]. Ann Oncol, 2019, 30(Suppl 5): mdz394.033.
[12]	Wang X, Li S, Sun Y, et al. The protocol of a prospective, multicenter, randomized, controlled phase Ⅲ study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-Ⅱ trial[J]. BMC Cancer, 2021, 21(1): 20.
[13]	Sah BK, Zhang B, Zhang H, et al. Neoadjuvant FLOT versus SOX phase Ⅱ randomized clinical trial for patients with locally advanced gastric cancer[J]. Nat Commun, 2020, 11(1): 6093.
[14]	Wang J, Saukel GW, Garberoglio CA, et al. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: A case report[J]. J Hematol Oncol, 2010, 3: 31.
[15]	Wagner AD, Grabsch HI, Mauer M, et al. EORTC-1203-GITCG- the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase Ⅱ-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group[J]. BMC Cancer, 2019, 19(1): 494.
[16]	Silva ND, Schulz L, Paterson A, et al. Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma[J]. Br J Cancer, 2015, 113(9): 1305-1312.
[17]	Zheng Y, Yang X, Yan C, et al. Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase Ⅱ trial[J]. Eur J Cancer, 2020, 130: 12-19.
[18]	Matsui H, Shimizu Y, Tachikawa H, et al. Locally advanced gastric cancer responding to neoadjuvant chemotherapy with ramucirumab plus paclitaxel-case report[J]. Gan To Kagaku Ryoho, 2019, 46(10): 1565-1567.
[19]	Stahl M, Maderer A, Lordick F, et al. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: randomized phase Ⅱ study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)[J]. Eur J Cancer, 2018, 93: 119-126.
[20]	Moehler MH, Janjigian YY, Adenis A, et al. CheckMate 649: A randomized, multicenter, open-label, phase Ⅲ study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer [abstract] [J]. J Clin Oncol, 2018, 36(4 suppl): TPS192.
[21]	Bang YJ, Van Cutsem E, Fuchs CS, et al. KEYNOTE-585: phase Ⅲ study of perioperative chemotherapy with or without pembrolizumab for gastric cancer[J]. Future Oncol, 2019, 15(9): 943-952.
[22]	Chubenko V, Inusilaev G, Imyanitov E, et al. Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer[J]. BMJ Case Rep, 2020, 13(9): e236144.
[23]	Liu L, Liu Y, Gong L, et al. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: A case report and review of the literature[J]. Cancer Biol Ther, 2020, 21(11): 983-989.
[24]	Hu SB, Liu CH, Wang X, et al. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer[J]. World J Surg Oncol, 2019, 17(1): 3.
[25]	Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer Manag Res, 2017, 9: 849-867.
[26]	Gong W, Zhao L, Dong Z, et al. After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients[J]. J Clin Lab Anal, 2018, 32(5): e22364
[27]	Sun Z, Zhang N. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy[J]. World J Surg Oncol, 2014, 12: 397.
[28]	Tan B, Li Y, Di Y, et al. Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer[J]. J Clin Lab Anal, 2018, 32(4): e22363.
[29]	Gertsen EC, Jongh C, Brenkman HJF, et al. The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer[J]. Eur J Surg Oncol, 2020, 46(7): 1247-1253.
[30]	Sun K, Hu H, Chen S, et al. CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer[J]. BMC Cancer, 2020, 20(1): 468.
[31]	Zhu Y, Sun Y, Hu S, et al. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: A retrospective study of 192 cases from National Cancer Center in China[J]. BMC Gastroenterol, 2017, 17(1): 41.
[32]	Li Z, Wang Y, Ying X, et al. Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: A propensity score-matched analysis[J]. BMC Cancer, 2019, 19(1): 80.
[33]	Rawicz-Pruszyński K, Ciseł B, Mlak R, et al. The role of the lymph node ratio in advanced gastric cancer after neoadjuvant chemotherapy[J]. Cancers (Basel), 2019, 11(12): 1914.
[34]	Kumazu Y, Oba K, Hayashi T, et al. Relationship between the waiting times for surgery and survival in patients with gastric cancer[J].World J Surg, 2020, 44(4): 1209-1215.
[35]	Liu Y, Zhang KC, Huang XH, et al. Timing of surgery after neoadjuvant chemotherapy for gastric cancer: impact on outcomes[J]. World J Gastroenterol, 2018, 24(2): 257-265.
[36]	Feng D, Leong M, Li T, et al. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy[J]. World J Surg Oncol, 2015, 13: 11.
[37]	Li Z, Shan F, Ying X, et al. Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A randomized clinical trial[J]. JAMA Surg, 2019, 154(12): 1093-1101.
[38]	Li Z, Shan F, Wang Y, et al. Laparoscopic versus open distal gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: safety and short-term oncologic results[J]. Surg Endosc, 2016, 30(10): 4265-4271.

Please choose a citation manager

Content to export